Australia's Lumos Diagnostics hits near 4-week high as co gets fresh funds

Lumos Diagnostics Holdings

03/10/2024 01:56

** Shares of Australia's Lumos Diagnostics  LDX.AX  rise as
much as 16.2% to A$0.043, their highest levels since Sept 6
    ** Stock posts its biggest intraday pct gain since Sept 25,
on track to record its second straight day of gains, if trend
holds 
    ** The medical equipment supplier says it has been awarded
A$3 mln ($2.06 mln) in funding from Biomedical Advanced Research
and Development Authority (BARDA), part of the U.S. Department
of Health and Human Services' administration
    ** Funding to support upcoming Lumos' FebriDx CLIA waiver
study and the U.S. FDA application 
    ** FebriDx can aid clinicians with appropriate antibiotic
use decisions and will hopefully improve antibiotic stewardship
- LDX
    ** Near 6.7 mln shares change hands, vs 30-day average
volume of 5.4 mln shares
    ** Stock has fallen 38.7% this year, as of 0044 GMT

    ($1 = 1.4535 Australian dollars)
    

 (Reporting by Roshan Thomas in Bengaluru)
 ((Roshan.Thomas@thomsonreuters.com))